Optimal control of treatment in a mathematical model of chronic myelogenous leukemia

Mathematical Biosciences

Volumn 210, Issue 1, 2007, Pages 143-156

  Nanda, Seema ^a   Moore, Helen ^b   Lenhart, Suzanne ^c  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^b AMERICAN INSTITUTE OF MATHEMATICS   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

CML; Drug therapy; Leukemia; Mathematical model; Optimal control

Indexed keywords

CYTOTOXICITY; MATHEMATICAL MODELS; OPTIMAL CONTROL SYSTEMS; ORDINARY DIFFERENTIAL EQUATIONS;

CANCER CELLS; CHRONIC MYELOGENOUS LEUKEMIA; LEUKEMIA;

DRUG THERAPY;

CYTARABINE; HYDROXYUREA; IMATINIB;

CANCER; DRUG; NUMERICAL MODEL;

ARTICLE; CANCER CELL; CANCER CONTROL; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; MATHEMATICAL MODEL; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTARABINE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MATHEMATICS; MODELS, BIOLOGICAL; PIPERAZINES; PYRIMIDINES; T-LYMPHOCYTES;

EID: 35248819749     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2007.05.003     Document Type: Article

References (46)

1. Adams B.M., Banks H.T., Kwon H.-D., and Tran H.T. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosc. Eng. 1 2 (2004) 223
2. Adimy M., Crauste F., and Ruan S. A mathematical study of the hematopoiesis process with applications to chronic myelogenous leukemia. SIAM J. Appl. Math. 65 4 (2005) 1328
3. Afenya E.K., and Bentil D. Some perspectives on modeling leukemia. Math. Biosci. 150 (1998) 113
4. Afenya E., and Calderón C. Diverse ideas on the growth kinetics of disseminated cancer cells. Bull. Math. Biol. 62 3 (2000) 527
5. Baccarani M., Martinelli G., Rosti G., Trabacchi E., Testoni N., Bassi S., Amabile M., Soverini S., Castagnetti F., Cilloni D., Izzo B., de Vivo A., Messa E., Bonifazi F., Poerio A., Luatti S., Giugliano E., Alberti D., Fincato G., Russo D., Pane F., Saglio G., and GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104 13 (2004) 4245
6. S.P. Chakrabarty, F.B. Hanson, Optimal control of drug delivery to brain tumors for a distributed parameters model, Proceedings of the American Control Conference (2005).
7. Clark C.W. Mathematical Bioeconomics: The Optimal Management of Renewable Resources (1990), Wiley, New York
8. In: Cohen Y. (Ed). Applications of Control Theory in Ecology (1987), Springer Verlag, New York
9. Duda Z. Numerical solutions to bilinear models arising in cancer chemotherapy. Nonlinear World 4 (1997) 53
10. Deininger M.W.N., and Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55 3 (2003) 401
11. Deininger M.W.N., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343
12. Deininger M.V.N., O'Brien S.G., Ford J.M., and Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21 (2003) 1637
13. Duvall C.P., and Perry S. The use of 51-chromium in the study of leukocyte kinetics in chronic myelocytic leukemia. J. Lab. Clin. Med. 71 (1968) 614
14. Eisen M. Mathematical Methods and Models in the Biological Sciences, Nonlinear and Multidimensional Theory (1988), Prentice Hall, New Jersey
15. + T-cell subpopulations. J. Theor. Biol. 170 (1994) 367
16. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341 3 (1999) 164
17. Fister K.R., and Panetta J.C. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60 (2000) 1059
18. Fister K.R., Lenhart S., and McNally J.S. Optimizing chemotherapy in an HIV model. Electron. J. Differential Equations 32 (1998) 1
19. Fleming W.H., and Rishel R.W. Deterministic and Stochastic Optimal Control (1975), Springer-Verlag, New York
20. Fokas A.S., Keller J.B., and Clarkson B.D. Mathematical model of granulocytopoesis and chronic myelogenous leukemia. Cancer Res. 51 (1991) 2084
21. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 349 (2003) 1451
22. Janeway C.A., Travers P., Walport M., and Shlomchik M. Immunobiology: The Immune System in Health and Disease (2001), Garland Publishing, New York
23. Jung E., Lenhart S., and Feng Z. Optimal control of treatments in a two-strain tuberculosis model. Discrete Contin. Dyn. Syst. Ser. B 2 (2002) 473
24. Kamien M.I., and Schwartz N.L. Dynamic Optimization: The Calculus of Variations and Optimal Control in Economics and Management (1991), Elsevier Science, New York
25. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., and Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97 (2001) 1999
26. Kirschner D., Lenhart S., and Serbin S. Optimal control of the chemotherapy of HIV. J. Math. Biol. 35 (1997) 775
27. Kuznetsov V., Makalkin I., Taylor M., and Perelson A. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 56 2 (1994) 295
28. Ledzewicz U., and Schattler H. Analysis of a cell cycle specific model for cancer chemotherapy. J. Biol. Syst. 10 (2002) 183
29. Leukemia and Lymphoma Society pamphlet, March 2005. Chronic Myelogenous Leukemia. http://www.leukemia-lymphoma.org/attachments/National/br-1114197910.pdf.
30. Mackey M.C., and Pujo-Menjouet L. Contribution to the study of periodic chronic myelogenous leukemia. C. R. Biol. 327 3 (2004) 235
31. Martin R., and Teo K.L. Optimal Control of Drug Administration in Cancer Chemotherapy (1994), World Scientific, New Jersey
32. Michor F., Hughes T., Iwasa Y., Branford S., Shah N.P., Sawyers C., and Nowak M. Dynamics of chronic myeloid leukemia. Nature 435 (2005) 1267
33. Mohri H., Perelson A., Tung K., Ribeiro R., Ramratnam B., Markowitz M., Kost R., Hurley A., Weinberger L., Cesar D., Hellerstein M., and Ho D. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194 9 (2001) 1277
34. Moore H., and Li N.K. A mathematical model of chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227 (2004) 513
35. Murray J.M. Some optimal control problems in cancer chemotherapy with a toxicity limit. Math. Biosci. 100 1 (1990) 49
36. Murray J.M. Optimal control for a cancer chemotherapy problem with general growth and cost functions. Math. Biosci. 98 (1990) 273
37. Neumann A.U., Lam N., Gretch D.R., Dahari D., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in-vivo and the anti-viral efficacy of interferon-a therapy. Science 282 (1998) 103
38. Pontryagin L.S., Boltyanskii V.G., Gamkrelidze R.V., and Mishchenko E.F. The Mathematical Theory of Optimal Processes (1962), Wiley, New Jersey
39. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340 17 (1999) 1330
40. Sethi S.P., and Thompson G.L. Optimal Control Theory: Applications to Management Science and Economics. second ed. (2000), Kluwer, Boston
41. Song J., and Yu J. Population System Control (1988), Springer-Verlag, New York
42. Swan G.W. Role of optimal control theory in cancer chemotherapy. Math. Biosci. 101 2 (1990) 237
43. Swierniak A., Polanski A., and Kimmel M. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Proliferation 29 (1996) 117
44. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., and Druker B.J. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Ablpositive cells. Blood 96 (2000) 3195
45. Topaly J.W., Zeller J., and Fruehauf S. Synergistic activity of the new ANL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15 3 (2001) 342
46. van Rhee F., Szydlo R.M., Hermans J., Devergie A., Frassoni F., Arcese W., de Witte T., Kolb H.J., Niederwiser D., Jacobsen N., Gahrton G., Bandini G., Carreras E., Bacigalupo A., Michallet M., Ruutu T., Reiffers J., Goldman J.M., Apperley J., and Gratwohl A. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20 7 (1997) 553